Geode Capital Management LLC Purchases 53,884 Shares of Becton, Dickinson and Company $BDX

Key Points

• Geode Capital Management increased its Becton, Dickinson stake by 0.8% in the fourth quarter, buying 53,884 additional shares and bringing its total holding to 6.89 million shares valued at about $1.33 billion.
• Institutional ownership remains heavy, with firms like Vanguard, State Street, and First Eagle also boosting positions; overall, 86.97% of BDX shares are owned by institutions.
• BDX reported stronger-than-expected quarterly results, with EPS of $2.90 and revenue of $4.71 billion, while analysts currently rate the stock Hold on average with a consensus price target of $183.64.

Geode Capital Management LLC boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 0.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,885,361 shares of the medical instruments supplier's stock after purchasing an additional 53,884 shares during the quarter. Geode Capital Management LLC owned about 2.42% of Becton, Dickinson and Company worth $1,331,165,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Becton, Dickinson and Company by 13.0% in the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier's stock valued at $7,118,282,000 after acquiring an additional 4,223,149 shares during the last quarter. State Street Corp increased its stake in shares of Becton, Dickinson and Company by 3.4% in the 3rd quarter. State Street Corp now owns 13,872,395 shares of the medical instruments supplier's stock valued at $2,596,496,000 after acquiring an additional 459,219 shares during the last quarter. First Eagle Investment Management LLC increased its stake in shares of Becton, Dickinson and Company by 16.5% in the 4th quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier's stock valued at $2,260,139,000 after acquiring an additional 1,651,592 shares during the last quarter. Massachusetts Financial Services Co. MA increased its stake in shares of Becton, Dickinson and Company by 3.7% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 9,486,694 shares of the medical instruments supplier's stock valued at $1,841,083,000 after acquiring an additional 336,110 shares during the last quarter. Finally, Wellington Management Group LLP increased its stake in shares of Becton, Dickinson and Company by 9,056.3% in the 3rd quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier's stock valued at $979,290,000 after acquiring an additional 5,174,944 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

BDX has been the subject of a number of recent analyst reports. Argus lowered their price target on Becton, Dickinson and Company from $230.00 to $180.00 and set a "buy" rating for the company in a research note on Monday, March 23rd. TD Cowen lowered their price target on Becton, Dickinson and Company from $189.00 to $163.00 and set a "hold" rating for the company in a research note on Monday, May 4th. Barclays upped their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an "overweight" rating in a research note on Monday, May 11th. Royal Bank Of Canada set a $175.00 price target on Becton, Dickinson and Company in a research note on Tuesday, April 14th. Finally, Zacks Research raised Becton, Dickinson and Company from a "strong sell" rating to a "hold" rating in a research note on Friday, April 10th. Seven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of "Hold" and a consensus price target of $183.64.

Becton, Dickinson and Company Price Performance

NYSE BDX opened at $148.36 on Friday. The business has a 50 day simple moving average of $151.84 and a 200 day simple moving average of $177.23. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. The stock has a market cap of $40.88 billion, a price-to-earnings ratio of 37.56, a PEG ratio of 10.42 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business had revenue of $4.71 billion during the quarter, compared to analysts' expectations of $4.67 billion. During the same period in the prior year, the business earned $3.35 EPS. Becton, Dickinson and Company's revenue for the quarter was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Analysts anticipate that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.8%. Becton, Dickinson and Company's dividend payout ratio is 106.33%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.